Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 1:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 250 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Polymorphism Clear all

Conditions: CYP2D6 Polymorphism
Interventions: Isotretinoin, dextromethorphan; Drug
Lead sponsor: University of Washington; Other
Eligibility: 12 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cancer Of Prostate, Prostate Cancer, Prostatic Neoplasms, Metastatic Prostate Cancer, Prostate
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Labor Pain, Post-cesarean Delivery
Interventions: Blood Draw; Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 293 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia Type 1
Interventions: S48168 (ARM210), Matching Placebo; Drug
Lead sponsor: RyCarma Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Age-Related Maculopathy
Interventions: Lucentis; Drug
Lead sponsor: University of Utah; Other
Eligibility: 50 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Santa Barbara, California • Denver, Colorado • Salt Lake City, Utah

Conditions: Sexual Addiction
Interventions: No Intervention; Other
Lead sponsor: American Foundation for Addiction Research; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 8
States / cities: Scottsdale, Arizona • Wickenburg, Arizona • Los Angeles, California + 4 more

Conditions: Genetic Polymorphisms
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Cryptococcosis
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Polymorphism- Genetic, Reward Mediating System
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Yohimbine; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Genetics in Hypertension
Interventions: low sodium diet, high sodium diet, renal plasma flow, SIEA collection; Other · Procedure
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: Abiraterone - Usual, Abiraterone - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 22 Years to 75 Years · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions: Flecainide Acetate, Placebo, Beta blocker; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 5 Years to 99 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Orange, California • New York, New York + 7 more

Conditions: Patients With Symptoms of Cardiac Arrhythmia at Risk for Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Scripps Translational Science Institute; Other
Eligibility: 18 Years and older
Enrollment: 928 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Colorectal Cancer
Interventions: Magnesium glycinate, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2025
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypothyroidism
Interventions: Levothyroxine, Levothyroxine Plus Liothyronine, Desiccated Thyroid Extract; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2015
U.S. locations: 1
States / cities: Besthesda, Maryland

Conditions: PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
Interventions: Rituximab, Brentuximab Vedotin, Bendamustine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: New Haven, Connecticut • Rochester, Minnesota

Conditions: Cancer
Interventions: Blood Sampling; Procedure
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Alcoholism
Interventions: acamprosate; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: HIV Infections, Hyperlipidemia
Interventions: Pravastatin, Darunavir, Ritonavir, Washout; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Standard of care or genotyping dosing of warfarin dosing; Drug
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Postsurgical Hypothyroidism, Hypothyroidism
Interventions: thyroidectomy, levothyroxine in thyroidectomy patients; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: SCLC
Interventions: Topotecan - usual, Topotecan - study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Medical Director, IRB Chair; Industry
Eligibility: 24 Years to 64 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Stuttering
Interventions: Not listed
Lead sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD); NIH
Eligibility: Not listed
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Effects of Isotretinoin on CYP2D6 Activity

Collection of Blood From Patients With Prostate Cancer

Mu-Opioid Receptor Genetic Polymorphism and Intrathecal Analgesia

Treatment of an Inherited Ventricular Arrhythmia

Study Evaluating Genotypes Using Lucentis

A Study of Gene Polymorphisms Associated With Specific Presentations of Sexual Addiction

NIEHS/UNC Environmental Polymorphism Study

Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection

Imaging and Genetic Investigation of Learning and Decision Making

Brain Receptors in Sympathetic Nervous System Regulation

Beta-2 Adrenergic Receptor Polymorphic Variants: An Endotype of Salt Sensitive Hypertension (Beta2AR).

Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms

Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia

THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring

Precision-Based Magnesium Trial

Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

Thiopurine Methyltransferase Polymorphisms Evaluation

Acamprosate: Genes Associated With Response

Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin

A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms

Genetic Factors Related to Stuttering